- Home
- ADSE vs NUVB Comparison
ADSE vs NUVB Comparison
Compare ADSE & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADSE
- NUVB
- Stock Information
- Founded
- ADSE 1980
- NUVB 2018
- Country
- ADSE Ireland
- NUVB United States
- Employees
- ADSE N/A
- NUVB N/A
- Industry
- ADSE Industrial Specialties
- NUVB Biotechnology: Pharmaceutical Preparations
- Sector
- ADSE Consumer Discretionary
- NUVB Health Care
- Exchange
- ADSE Nasdaq
- NUVB Nasdaq
- Market Cap
- ADSE 728.1M
- NUVB 850.3M
- IPO Year
- ADSE N/A
- NUVB N/A
- Fundamental
- Price
- ADSE $13.24
- NUVB $2.63
- Analyst Decision
- ADSE Hold
- NUVB Strong Buy
- Analyst Count
- ADSE 1
- NUVB 6
- Target Price
- ADSE $14.00
- NUVB $6.33
- AVG Volume (30 Days)
- ADSE 93.5K
- NUVB 2.1M
- Earning Date
- ADSE 09-12-2024
- NUVB 11-06-2024
- Dividend Yield
- ADSE N/A
- NUVB N/A
- EPS Growth
- ADSE N/A
- NUVB N/A
- EPS
- ADSE N/A
- NUVB N/A
- Revenue
- ADSE $158,974,606.00
- NUVB $2,162,000.00
- Revenue This Year
- ADSE $98.67
- NUVB N/A
- Revenue Next Year
- ADSE $47.66
- NUVB N/A
- P/E Ratio
- ADSE N/A
- NUVB N/A
- Revenue Growth
- ADSE 168.42
- NUVB N/A
- 52 Week Low
- ADSE $6.10
- NUVB $1.21
- 52 Week High
- ADSE $15.01
- NUVB $4.16
- Technical
- Relative Strength Index (RSI)
- ADSE 43.56
- NUVB 51.75
- Support Level
- ADSE $13.18
- NUVB $2.18
- Resistance Level
- ADSE $14.33
- NUVB $3.07
- Average True Range (ATR)
- ADSE 0.70
- NUVB 0.17
- MACD
- ADSE -0.14
- NUVB 0.05
- Stochastic Oscillator
- ADSE 14.58
- NUVB 49.44
About ADSE ADS-TEC ENERGY PLC
ADS-TEC Energy PLC produces, develops, and markets battery-buffered EV charging systems infrastructure, battery storage systems, and cloud-based services which enable the customer to control and manage the system. Geographically, it derives a majority of its revenue from Europe.
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).